Aggressive combo therapy takes on tough brain cancer
NCT ID NCT07670026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether an intensified treatment plan can delay tumor growth in adults with high-risk glioblastoma that was only partially removed or came back quickly. Participants receive higher radiation doses to the remaining tumor, plus chemotherapy and two immunotherapy drugs (sintilimab and bevacizumab) for up to a year. The study will track how long people live without their cancer worsening, overall survival, side effects, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab, bevacizumab, temozolomide, and higher-dose radiation
What this could lead to
If it works, this could point toward a more effective treatment strategy for high-risk glioblastoma that is hard to treat with standard therapy.
What could go wrong
This is a small, early-phase (phase II) study with only 31 participants, so results may not apply to all patients. The intensified regimen also carries higher risks of side effects like radiation necrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital,School of Medicine,Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••